Business
Resverlogix Notice of Conference Call & Webcast to Provide a Market Update
Resverlogix Notice of Conference Call & Webcast to Provide a Market Update
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\n Nov. 25, 2010 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, Nov. 25 /CNW/ - Resverlogix Corp. (TSX:RVX) announced today\n that it will host a live teleconference and webcast on Monday, November\n 29, 2010 at 11:00 am Mountain time. The purpose of the teleconference\n is to provide a market update from management.\n\n\nThe dial-in numbers for this event are toll free 1-800-319-4610 and\n international 1-604-638-5340. A link for this webcast will be posted\n onto the homepage of Resverlogix's website and can be accessed from the\n following address http://services.choruscall.com/links/resverlogix101129.html.\n\n\n\nThe webcast will be available on the Resverlogix website for replay for\n a period of 45 days after the event.\n\n\nAbout Resverlogix Corp.\n\n\nResverlogix Corp. is a leading biotechnology company engaged in the\n development of novel therapies for important global medical markets\n with significant unmet medical needs. The NexVas™ PR program is the\n Company's primary focus which is to develop novel small molecules that\n enhance ApoA-1. These vital therapies address the burden of\n atherosclerosis and other important diseases such as Acute Coronary\n Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and\n other vascular disorders. Resverlogix Corp.'s common shares trade on\n the Toronto Stock Exchange (TSX:RVX). For further information please\n visit www.resverlogix.com.\n\n\nThis media alert may c...